The study on the relationship between serum vascular endothelial growth factor and proteinuria in adriamycin-induced nephrotic rats

Journal of Huazhong University of Science and Technology (Impact Factor: 0.83). 12/2001; 21(4):301-303. DOI: 10.1007/BF02886562


To study the relationship between serum vascular endothelial growth factor (VEGF) and proteinuria in adriamycin-induced nephrotic
rats, a rat model of adriamycin-induced nephrotitis was developed by injection of adriamycin into a tail vein in a rat. At
different time points, 24-h urinary protein excretion was measured by using Coomassie brilliant blue method and the serum
VEGF levels detected by using ELISA assay. The interventional effect of VEGF on this model was observed. The results showed
that: (1) The adriamycin-induced nephrotic syndrome rat model was developed successfully; (2) Serum VEGF levels and proteinuria
were significantly increased at 7th day after intravenous injection of adriamycin. There was a positive correlation between
serum VEGF levels and 24-h urinary protein excretion (r=0. 67,P<0. 05). (3) The 24-h urinary protein excretion was significantly increased in the rats receiving administration of VEGF (P<0. 05). It was concluded that VEGF might play an important role in the pathogenesis of proteinuria in adriamycin-induced
nephrotic rats.

1 Follower
3 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present study was designed to test the therapeutic effect of a new antimalarial drug, artesunate in experimental model of nephrotic syndrome. To induce this experimental model, Adriamycin was given once by a single intravenous injection (7.5 mg/kg) through the tail vein. Six days after injection of Adriamycin, therapeutic protocol was developed by intraperitoneally (IP) administration of 5 mg/kg artesunate (ARS). Total of IP injections were 14, of which 5 injections were made every day and 9 injections were carried out at regular 48-h intervals. Therapeutic protocol was terminated on day 28 and animals were killed on day 49. The results showed that treatment with ARS caused a significant reduction in the level of proteinuria, urine urea and urine sodium compared with nontreated controls. In addition, decrease in serum triglyceride and increase in the level of serum albumin was significant in treated group with ARS compared with nontreated controls. Moreover, treatment with ARS significantly reduced glomerular polymorphonuclear (PMN) and mononuclear cells infiltration, hypercellularity, karyorrhexis, wire loops, and hydropic change in capillary network within the renal cortex, as well as decreased hyalin casts. On the other hand, healthy controls receiving ARS showed a significant decrease in amounts of serum triglyceride, urine urea, and urine sodium and potassium compared with normal group. These data suggest that artesunate therapy can ameliorate proteinuria, and suppress the progression of glomerular lesions in experimental model of nephrotic syndrome; it may also be recommended as a lipid-lowering drug.
    International Journal of Toxicology 07/2007; 26(4):373-80. DOI:10.1080/10915810701493293 · 1.29 Impact Factor